Ocrelizumab (Ocrevus) has now been approved for use in Canada for the treatment of adults with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features. An application was also submitted for use in primary-progressive MS, but has not yet received approval. The drug was approved by the U.S. Food and Drug Administration earlier this year (see FDA approves ocrelizumab in RRMS, PPMS, NeuroSens, March 30, 2017). Read More
Latest News
IVIG: limited benefit in Alzheimer’s disease
August 2, 2017Two recent studies have reported on the effects of intravenous immunoglobulin in patients with cognitive impairment due to Alzheimer’s disease. Read More
Delays in diagnosis, treatment: MS patient survey
July 19, 2017Most MS patients are older at diagnosis, often delay starting treatment, and are likely to remain with the first-choice treatment, according to a survey conducted on MSology, the sister site of NeuroSens. Read More
Progressive MS studies
May 19, 2017REPORT FROM AAN – BOSTON, MA, APRIL 22-28, 2017 AAN 2017: There is a growing body of data on the use of disease-modifying therapies in patients with progressive multiple sclerosis. The following is a summary of key studies presented at AAN 2017. Read More